177Lu-DOTA-EB-TATE is a theranostic agent based on octreotate that uses an Evans blue structure to bind albumin to improve the pharmacokinetics and pharmacodynamics.
177Lu-DOTA-EB-TATE is a modified molecule that brings some biological advantages but above all allows going around the patents filed for 177Lu-Lutathera and hence, can find applications in the same type of indications as this marketed drug. The authors claim that this drug shows remarkably higher uptake and retention in NET tumors.
A first pilot study aiming to evaluate the efficacy of a single low-dose treatment in patients with advanced neuroendocrine neoplasm (NEN) was performed and results were published in May 2018. 68Ga-DOTATATE was used to select and follow-up the patients.
Target/Mechanism: somatostatin receptors
Leading Emitter: beta electrons (β–)